einstein (São Paulo). 06/Aug/2020;18:eAI5452.
Topical tofacitinib in treatment of alopecia areata
DOI: 10.31744/einstein_journal/2020AI5452
Alopecia areata is an autoimmune disease and the second most frequent cause of non-scarring hair loss. Several treatments have been described but are associated to low efficacy, particularly in the more resistant clinical forms. Janus kinase inhibitors are a new therapeutic option, and it may become the first line treatment in the next few years, as topical or oral use.( – )
A 23-year-old female white female patient, with a history of alopecia areata for 12 years, presented diffuse hair loss in the scalp and part of the eyebrow. She had used oral steroids, cyclosporin and methotrexate, with no response on the right eyebrow ( ). She initiated on topical tofacitinib 2% (Chemistry Rx Compound and Specialty Pharmacy, Philadelphia, USA), once a day, and follow-up every 4 weeks. Hair growth was observed 4 weeks after initiating treatment ( ) and, two months later, there was complete hair growth of the eyebrow and of other alopecia sites. Four months after discontinuing the treatment, she maintains a positive response ( ).
[…]
7,557
